Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEODOC study of tumor-lysate loaded cross-presenting dendritic cells in epithelial ovarian cancer
NL-OMON59919Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2023
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of XP-DC + tumor lysate + keyhole limpet hemocyanin in ovarian cancer and epithelial ovarian cancer (EOC), sponsored by Radboud University Medical Center. Primary endpoint: Immune response induced or enhanced by autologous tumor lysate-loaded XP-DC. Started Apr 2023; status: completed.
02
Drugs
XP-DC + tumor lysate + keyhole limpet hemocyanin
03
Conditions
ovarian cancerepithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NL-OMON59919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59919.